AG-ZOLPIDEM ODT DIN 02542390
Health Canada record
| Active ingredient(s) | ZOLPIDEM TARTRATE 10 MG |
|---|---|
| Dosage form | Tablet (Orally-Disintegrating) |
| Route | Sublingual |
| Schedule | TARGETED SUBSTANCES (CDSA IV) |
| Class | Human |
| ATC | N05CF02 ZOLPIDEM |
| Original market date | |
| Current status date | 16-Oct-2023 |
| Source | Health Canada DPD |
Establishment licence of the holder
Angita Pharma Inc. — licence 101870, currently licensed, last inspection rating C (2025-01-13).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing ZOLPIDEM TARTRATE
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02542382 | AG-ZOLPIDEM ODT | ANGITA PHARMA INC. | Tablet (Orally-Disintegrating) | ZOLPIDEM TARTRATE 5 MG | Approved |
| 02434946 | APO-ZOLPIDEM ODT | APOTEX INC | Tablet (Orally-Disintegrating) | ZOLPIDEM TARTRATE 10 MG | Marketed |
| 02436159 | APO-ZOLPIDEM ODT | APOTEX INC | Tablet (Orally-Disintegrating) | ZOLPIDEM TARTRATE 5 MG | Marketed |
| 02540592 | JAMP ZOLPIDEM ODT | JAMP PHARMA CORPORATION | Tablet (Orally-Disintegrating) | ZOLPIDEM TARTRATE 5 MG | Marketed |
| 02540606 | JAMP ZOLPIDEM ODT | JAMP PHARMA CORPORATION | Tablet (Orally-Disintegrating) | ZOLPIDEM TARTRATE 10 MG | Marketed |
| 02472821 | MINT-ZOLPIDEM ODT | MINT PHARMACEUTICALS INC | Tablet (Orally-Disintegrating) | ZOLPIDEM TARTRATE 5 MG | Marketed |
| 02472848 | MINT-ZOLPIDEM ODT | MINT PHARMACEUTICALS INC | Tablet (Orally-Disintegrating) | ZOLPIDEM TARTRATE 10 MG | Marketed |
| 02436175 | PMS-ZOLPIDEM ODT | PHARMASCIENCE INC | Tablet (Orally-Disintegrating) | ZOLPIDEM TARTRATE 5 MG | Marketed |
| 02436183 | PMS-ZOLPIDEM ODT | PHARMASCIENCE INC | Tablet (Orally-Disintegrating) | ZOLPIDEM TARTRATE 10 MG | Marketed |
| 02537346 | PRO-ZOLPIDEM ODT | PRO DOC LIMITEE | Tablet (Orally-Disintegrating) | ZOLPIDEM TARTRATE 5 MG | Marketed |
| 02537354 | PRO-ZOLPIDEM ODT | PRO DOC LIMITEE | Tablet (Orally-Disintegrating) | ZOLPIDEM TARTRATE 10 MG | Marketed |
| 02370433 | SUBLINOX | BAUSCH HEALTH, CANADA INC. | Tablet (Orally-Disintegrating) | ZOLPIDEM TARTRATE 10 MG | Marketed |
| 02391678 | SUBLINOX | BAUSCH HEALTH, CANADA INC. | Tablet (Orally-Disintegrating) | ZOLPIDEM TARTRATE 5 MG | Marketed |
| 02439638 | ZOLPIDEM TARTRATE ODT | BAUSCH HEALTH, CANADA INC. | Tablet (Orally-Disintegrating) | ZOLPIDEM TARTRATE 10 MG | Approved |
| 02439646 | ZOLPIDEM TARTRATE ODT | BAUSCH HEALTH, CANADA INC. | Tablet (Orally-Disintegrating) | ZOLPIDEM TARTRATE 5 MG | Approved |
| 02205971 | IVADAL | SANOFI-AVENTIS CANADA INC | Tablet | ZOLPIDEM TARTRATE 5 MG | Cancelled Pre Market |
| 02205998 | IVADAL | SANOFI-AVENTIS CANADA INC | Tablet | ZOLPIDEM TARTRATE 10 MG | Cancelled Pre Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 31858 | 2023-10-16 | Abbreviated New Drug Submission (ANDS) | Administrative: Licensing Agreement Between Two Manufacturers |
International API supply for ZOLPIDEM TARTRATE
14 valid EDQM Certificates of Suitability from 14 holders. 20 active FDA Drug Master Files.
Request a quote for AG-ZOLPIDEM ODT